Stoke Therapeutics, Inc.STOKNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR+19.4%
5Y CAGR-12.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+19.4%/yr
vs -35.3%/yr prior
5Y CAGR
-12.9%/yr
Recent acceleration
Acceleration
+54.7pp
Accelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 37.49% |
| 2024 | 18.08% |
| 2023 | 6.16% |
| 2022 | 22.03% |
| 2021 | 53.01% |
| 2020 | 74.98% |
| 2019 | 170.16% |
| 2018 | 125.46% |
| 2017 | 0.00% |